scholarly journals Treatment with Inhaled Mometasone Furoate Reduces Short-Acting β2 Agonist Claims and Increases Adherence Compared to Fluticasone Propionate in Asthma Patients

2011 ◽  
Vol 14 (2) ◽  
pp. 339-346 ◽  
Author(s):  
Prakash Navaratnam ◽  
Howard S. Friedman ◽  
Eduardo Urdaneta
Keyword(s):  
Fluticasone Propionate ◽  
Mometasone Furoate ◽  
Short Acting ◽  
Asthma Patients ◽  
Β2 Agonist

Mometasone Furoate/Formoterol Combination Therapy Increases Frequency of Days/Nights Free of Short-Acting β2-Agonist Use

2011 ◽  
Vol 127 (2) ◽  
pp. AB86-AB86
Author(s):  
A.S. Nayak ◽  
R.A. Nathan ◽  
E.O. Meltzer ◽  
S.F. Weinstein ◽  
H. Nolte
Keyword(s):  
Combination Therapy ◽  
Mometasone Furoate ◽  
Short Acting ◽  
Β2 Agonist

scholarly journals The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Cheng-Yi Wang ◽  
Chih-Cheng Lai ◽  
Ya-Hui Wang ◽  
Hao-Chien Wang
Keyword(s):  
Acute Exacerbation ◽  
Pay For Performance ◽  
Inhaled Corticosteroids ◽  
Severe Exacerbation ◽  
Short Acting ◽  
Increased Risk ◽  
All Cause Mortality ◽  
Asthma Patients ◽  
Β2 Agonist ◽  
Β2 Agonists

AbstractThis study aims to investigate the prevalence of short-acting β2-agonist (SABA) overuse in asthma and the associated risk of acute exacerbation and mortality in Taiwan. We used the Taiwanese pay-for-performance asthma program database, which included patients aged between 12 and 100 years who were enrolled in the program between 2001 and 2015. Among a total of 218,039 patients, 34,641 (15.9%) patients are classified as SABA over-users. Compared with patients who did not receive inhaled corticosteroids (ICS) and collected ≤2 canisters, SABA over-users had a higher risk of severe exacerbations. SABA over-users had a higher risk of all-cause mortality compared with patients who did not receive ICS and collected ≤2 canisters. The overall prevalence of SABA overuse in Taiwan is 15.9%, and this is even higher in concomitant ICS users. In addition, the overuse of SABA is associated with an increased risk of severe exacerbation and death.

Comparison between Compliance of Fluticasone Propionate Diskhaler and of Fluticasone Propionate Diskus in Adult Bronchial Asthma Patients

Respiration ◽  
2006 ◽  
Vol 73 (5) ◽  
pp. 680-684 ◽  
Author(s):  
Takashi Hasegawa ◽  
Eiichi Suzuki ◽  
Katsuya Fujimori ◽  
Takuro Sakagami ◽  
Shinichi Toyabe ◽  
...  
Keyword(s):  
Fluticasone Propionate ◽  
Bronchial Asthma ◽  
Asthma Patients
Sign in / Sign up

Export Citation Format

Share Document